Conference abstract · 2 Nov 2017
Conference abstractPublished 2 Nov 2017
Formulation and evaluation of novel particulate vaccine against gonorrhea
Mercer University, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Gonorrhea is one of the most common sexually transmitted infections caused by Gram-negative Diplococcus bacteria, Neisseria gonorrhea. In 2009 301,174 cases of gonorrhea were reported in the US which accounts for 99.1 cases per 100,000 people. Patients suffer from symptomatic urethritis and cervicitis, pelvic inflammation, pus discharge, abdominal pain and dyspareunia. The treatment for gonorrhea involves use of antimicrobials but development of drug resistance is a great threat to public health and therefore novel methods for prevention of gonorrhea infection are needed. In the present study, we formulated microneedles to deliver and evaluate efficacy of dead gonorrhea bacteria in microparticles as vaccine through transdermal route. N. gonorrhoeae were grown in GC Broth. Bacteria were then harvested by centrifugation and three washings were done using PBS solution followed by centrifugation to concentrate bacterial suspension. This concentrated bacterial suspension was used to prepare vaccine microparticles using pre-crosslinked BSA. To this solution, concentrated bacterial suspension was added and microparticles were prepared by spray drying using a 0.5 mm nozzle at 120Ã?°C, 100% aspirator and 20 ml/h speed. The microparticles obtained were characterized. The percent yield for vaccine particles was 89% w/w. The size of the particles was determined by using Malvern Zetasizer, vaccine particles were 4.5 um in size and poly dispersity index (PDI) was 0.447. The charge on the particles was -25.1Ã?±5.79 mV. Vaccine particles were successfully prepared and characterized for yield, size, PDI and charge. Future studies will involve evaluation of this particulate vaccine for inducing an immune response in in-vitro and in-vivo studies.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract
Novel particulate vaccine against Gonorrhea
Conference abstract · 2 Nov 2017
Immuno-strategies for cancer treatment including novel particulate cancer vaccines
Conference abstract · 2 Nov 2017
Novel particulate vaccines for infectious diseases
Conference abstract
Formulation and preclinical testing of novel particulate vaccines loaded into Oral Dissolving Films (ODF) for measles
More from this journal
The newest in Journal of Clinical and Cellular Immunology.
Perspective · 10 Sep 2026
Cellular Pathways Involved in Mucosal Immunity and Protection Against Environmental Challenges
Commentary · 22 Jul 2026
From Bench to Bedside: Reframing the CXCL13/CXCR5 Axis as a Non-Redundant Organizer of Protective Pulmonary Immunity in COVID-19
Commentary · 17 Jul 2026
CD5L:p40, a third wheel to IL-12 and IL-23 biology?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Cellular Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Lotika Bajaj”
- BylineArticles whose byline prints “Wael Gamal”
- BylineArticles whose byline prints “Martin J D’Souza”

